We are live on ! Find out more
ACM

ADAR1 Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 340.85%
This Fund
S&P 500
This Quarter Est. Return
+5.02%
1 Year Est. Return
+340.85%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$500M
AUM Growth
-$115M
Cap. Flow
-$85.2M
Cap. Flow %
-17.03%
Top 10 Hldgs %
48.26%
Holding
330
New
47
Increased
56
Reduced
65
Closed
116

Top Buys

Rank Stock Value
1
ZLAB icon
Zai Lab
ZLAB
+$14.3M
2
IKT icon
Inhibikase Therapeutics
IKT
+$12.7M
3
BIL icon
State Street SPDR Bloomberg 1-3 Month T-Bill ETF
BIL
+$10.1M
4
ABVX
Abivax
ABVX
+$9.13M
5
RVMD icon
Revolution Medicines
RVMD
+$6.34M

Top Sells

Rank Stock Value
1
RPRX icon
Royalty Pharma
RPRX
+$27.8M
2
CYTK icon
Cytokinetics
CYTK
+$25.8M
3
KROS icon
Keros Therapeutics
KROS
+$21.9M
4
BBIO icon
BridgeBio Pharma
BBIO
+$19.9M
5
ASND icon
Ascendis Pharma A/S
ASND
+$11.8M

Sector Composition

Rank Sector Weight
1 Healthcare 77.69%
2 Financials 3.07%
3 Communication Services 1.32%
4 Technology 0.33%
5 Consumer Staples 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RYTM icon
51
Rhythm Pharmaceuticals
RYTM
$7.72B
$1.73M 0.35%
+30,941
New +$1.71M
JANX icon
52
Janux Therapeutics
JANX
$982M
$1.69M 0.34%
31,509
+18,509
+142% +$979K
AXSM icon
53
Axsome Therapeutics
AXSM
$10.8B
$1.66M 0.33%
19,661
+19,061
+3,177% +$1.75M
SLNO
54
DELISTED
Soleno Therapeutics
SLNO
$1.66M 0.33%
36,830
+26,830
+268% +$1.39M
KALA icon
55
KALA BIO
KALA
$14.2M
$1.53M 0.31%
4,407
-1,714
-28% -$540K
KDK
56
Kodiak AI
KDK
$842M
$1.53M 0.3%
138,966
– –
INSM icon
57
Insmed
INSM
$28.9B
$1.52M 0.3%
21,974
+18,340
+505% +$1.32M
CDMO
58
DELISTED
Avid Bioservices, Inc. Common Stock
CDMO
$1.48M 0.3%
+120,000
New +$1.37M
JNJ icon
59
CALL
Johnson & Johnson
JNJ
$619B
$1.45M 0.29%
+10,000
New +$1.55M
SLRN
60
DELISTED
ACELYRIN
SLRN
$1.4M 0.28%
444,967
+391,467
+732% +$1.9M
VRNA
61
DELISTED
Verona Pharma
VRNA
$1.35M 0.27%
29,100
+19,100
+191% +$717K
RGNX icon
62
Regenxbio
RGNX
$745M
$1.32M 0.26%
170,129
-398,879
-70% -$3.75M
CAPR icon
63
CALL
Capricor Therapeutics
CAPR
$242M
$1.31M 0.26%
+95,000
New +$1.66M
PSTX
64
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
$1.29M 0.26%
+134,109
New +$700K
RPRX icon
65
Royalty Pharma
RPRX
$25.4B
$1.27M 0.25%
49,963
-1,046,703
-95% -$27.8M
CTNM
66
Contineum Therapeutics
CTNM
$577M
$1.2M 0.24%
82,234
+73,267
+817% +$1.16M
ACOG
67
Alpha Cognition
ACOG
$189M
$1.2M 0.24%
+204,348
New +$1.15M
GERN icon
68
Geron
GERN
$1.01B
$1.2M 0.24%
337,676
-219,483
-39% -$877K
LXEO icon
69
Lexeo Therapeutics
LXEO
$357M
$1.12M 0.22%
169,505
+112,339
+197% +$885K
LLY icon
70
Eli Lilly
LLY
$1.06T
$1.04M 0.21%
1,350
+200
+17% +$166K
IBIO icon
71
iBio
IBIO
$69.1M
$1.02M 0.2%
415,606
-60,606
-13% -$156K
ITOS
72
DELISTED
iTeos Therapeutics
ITOS
$1.01M 0.2%
131,599
-245,138
-65% -$2.11M
KZR
73
DELISTED
Kezar Life Sciences
KZR
$991K 0.2%
147,404
+13,577
+10% +$101K
OABI icon
74
OmniAb
OABI
$325M
$985K 0.2%
278,108
-1,059,194
-79% -$4.19M
REGN icon
75
Regeneron Pharmaceuticals
REGN
$79.5B
$969K 0.19%
1,361
+490
+56% +$411K
1 2
3
4 5

Similar funds

RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return

ADAR1 Capital Management's Q4 2024 Portfolio in Review

As of Q4 2024, ADAR1 Capital Management held 330 positions worth $500M, down 19% from $615M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

ADAR1 Capital Management withdrew a net $85.2M in Q4 2024, closing 116 positions and reducing 65 holdings. Its most notable exit was Syndax Pharmaceuticals, an estimated $6.74M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 78% of assets, down from 86% a quarter earlier, followed by Financials and Communication Services.

Against the trend, ADAR1 Capital Management opened a new position in Inhibikase Therapeutics worth $16.6M.

  • ADAR1 Capital Management's largest Q4 2024 buy was Inhibikase Therapeutics: 5,103,005 shares worth $16.6M.
  • ADAR1 Capital Management added most to Zai Lab in Q4 2024, an estimated $14.3M increase.
  • ADAR1 Capital Management's biggest Q4 2024 reduction was Royalty Pharma, cutting an estimated $27.8M.
  • ADAR1 Capital Management fully exited Syndax Pharmaceuticals in Q4 2024, selling an estimated $6.74M.
  • ADAR1 Capital Management's ten largest holdings make up 48% of its $500M portfolio in Q4 2024.
  • ADAR1 Capital Management opened 47 new positions and closed 116 in Q4 2024.
  • ADAR1 Capital Management's portfolio value fell 19% quarter-over-quarter to $500M.

Based on ADAR1 Capital Management's 13F filing for Q4 2024, filed 13 Feb 2025.